InflaRx maintains a dividend yield of 0.00%, reflecting the standard practice among clinical-stage biopharmaceutical enterprises that choose to reinvest all available capital into research and development, clinical trials, and pipeline expansion rather than distributing cash dividends. Income-focused investors seeking regular dividend payouts typically look toward established blue-chip equities or financial sector stocks, as emerging biotechnology firms prioritize funding scientific operations over shareholder income distributions.